WS #13331
Investors react negatively to potential $400B AZN-BMY merger, with AZN down 8%.
AstraZeneca-Bristol Myers merger rejected by investors
Investors react negatively to potential $400B AZN-BMY merger, with AZN down 8%.
Investors react negatively to potential $400B AZN-BMY merger, with AZN down 8%.
Investors react negatively to potential $400B AZN-BMY merger, with AZN down 8%.